Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
May 2018
-
Media ReleaseNovartis completes tender offer for all outstanding shares of AveXis, Inc.Basel, May 15, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Novartis AM…
-
Media ReleaseNovartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosisNew approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)[1] In a…
-
Machine learning poised to accelerate drug discovery
Technology used to tag friends on social media could change the way drug discovery is done.
-
Media ReleaseAlcon Cares Project 100 Commits to Reducing Cataract Blindness GloballyAlcon Cares to donate 100 reprocessed Infiniti® units to clinics helping underserved patients in Asia, Central and South America, and Africa over the next three years Program to increase…
-
Media ReleaseAveXis Reports First Quarter 2018 Financial and Operating Results-- Significant progress across operating functions including licensing, clinical trials and regulatory interactions -- -- AVXS-101 pre-BLA meeting with FDA is scheduled to be…
-
Key ReleaseSandoz receives complete response letter from the US FDA for proposed biosimilar rituximabHolzkirchen, May 2, 2018 - Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing…
-
T.J. Sharpe on why clinical trials matter
Melanoma survivor T.J. Sharpe discusses the importance of clinical trials to help raise awareness among the community.
-
Media ReleaseKymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphomaKymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response[1] Kymriah is the only…
-
Key ReleaseNovartis provides update on proposed acquisition of AveXisBasel, May 1, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") applicable to…
April 2018
-
Media ReleaseNovartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanomaTafinlar + Mekinist is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation, following complete surgical resection…
-
Media ReleaseNew Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment intervalPatients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week…
-
In The NewsHow Long Till the Final World Malaria Day?Deaths from malaria have been driven down by 60% since 2000. But unchecked drug resistance could cause more than 100,000 new deaths each year. Vas Narasimhan, CEO of Novartis, explains how we could…
Pagination
- ‹ Previous page
- 1
- …
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- …
- 152
- › Next page